ChemMedChem · 2011 · 39 citations · 27 references
MedicineMedicinal ChemistryOncologyCancer PharmacologyDrug DesignDrug DiscoveryCell Cycle PharmacologyCell Division InhibitionMicrotubule Assembly InhibitionMitotic InhibitorsAnticancer ActivityAnticancer ChemotherapyAurora Kinase InhibitionCell Cycle InhibitionCell Cycle InhibitorsInhibition Of Tubulin AssemblyMicrotubule Polymerization InhibitionTubulin Polymerization Inhibitors
A new class of nitrovinyl biphenyl compounds based on the structures of colchicines and allocolchicines were designed, synthesized, and shown to inhibit tubulin polymerization and cause mitotic arrest. A majority of these compounds were found to possess potent anticancer properties, with IC(50) values in the range of 0.05-7 μM, and are equally potent with colchicine in HeLa and MCF-7 cells. Compounds 14 e and 14 f inhibited tubulin assembly by more than 60 %, and flow cytometry studies indicated growth arrest of cells in the G(2)/M phase of the cell cycle in a concentration-dependent manner. Treatment of cells with 14 f resulted in upregulation of cyclin B1 and aurora kinase B mRNA levels, corresponding to growth arrest in the G(2)/M phase of the cell cycle as the mode of action.
27
Tubulin and microtubules as targets for anticancer drugs.
John A. Hadfield, Sylvie Ducki, Nicholas Hirst et al. · PubMed · 2003 · 247 citations
Medicine, Oncology, Pharmacology +12
Robert S. DiPaola · PubMed · 2002 · 198 citations